评论
打印
Nordisk's top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent
据研究报告表明，最畅销降糖药Victoza可降低心脏病中风，以及心血管死亡风险，减少比例达13%，
in a closely watched study that may help boost sales of the injectable medicine.
该项研究有望增加注射类药物销量。
Victoza is only the second diabetes drug to show such heart benefits.
Victoza也是全球第二种有益心脏的降糖药物。
John Buse, professor of medicine at the UNC School of Medicine, who worked on the study said,
来自北卡医学院的研究人员约翰·布斯认为，
"To me, the impressive thing about this trial is the consistency across clinical endpoints and its robustness."
我认为最让人感到意外的是，该药物在临床试验终点以及鲁棒性的一致性。
Because about half of deaths in people with diabetes are caused by heart disease,
在所有糖尿病患者中，大约一半都是因心脏疾病死亡，
reducing heart risk is considered essential to their care.
降低心脏病风险是治疗的重中之重。
译文属可可英语创，未经允许，不得转载。
